Vical Company Profile (NASDAQ:VICL)

About Vical

Vical logoVical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, and completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: VICL
  • CUSIP: 92560210
Key Metrics:
  • Previous Close: $2.86
  • 50 Day Moving Average: $3.26
  • 200 Day Moving Average: $3.93
  • 52-Week Range: $2.80 - $5.40
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.95
  • P/E Growth: 0.00
  • Market Cap: $26.33M
  • Outstanding Shares: 9,206,000
  • Beta: 1.88
  • Net Margins: -30.81%
  • Return on Equity: -14.18%
  • Return on Assets: -12.90%
  • Current Ratio: 12.38%
  • Quick Ratio: 12.38%
Additional Links:
Companies Related to Vical:

Analyst Ratings

Consensus Ratings for Vical (NASDAQ:VICL) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.00 (179.72% upside)

Analysts' Ratings History for Vical (NASDAQ:VICL)
DateFirmActionRatingPrice TargetDetails
9/22/2016HC WainwrightReiterated RatingBuy$11.00 -> $8.00View Rating Details
6/23/2015Roth CapitalDowngradeBuy -> Neutral$4.65 -> $1.65View Rating Details
(Data available from 10/24/2014 forward)


Earnings History for Vical (NASDAQ:VICL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/27/2016($0.25)N/AView Earnings Details
8/9/2016Q216($0.28)($0.14)$4.50 million$4.10 millionViewN/AView Earnings Details
5/9/2016Q116($0.04)($0.03)$6.88 million$4.60 millionViewN/AView Earnings Details
3/14/2016Q415($0.02)($0.03)$4.82 million$6.81 millionViewListenView Earnings Details
7/30/2015Q215($0.06)($0.03)$3.80 million$4.20 millionViewListenView Earnings Details
5/8/2015Q115($0.05)($0.04)$2.50 million$4.90 millionViewN/AView Earnings Details
2/26/2015Q414($0.05)($0.05)$4.82 millionViewN/AView Earnings Details
10/30/2014Q314($0.05)($0.05)$2.50 million$3.40 millionViewN/AView Earnings Details
7/31/2014Q214($0.05)($0.05)$1.90 million$4.50 millionViewN/AView Earnings Details
5/1/2014Q114($0.05)($0.04)$1.60 million$2.40 millionViewN/AView Earnings Details
2/11/2014Q413($0.09)($0.03)$1.54 million$3.15 millionViewN/AView Earnings Details
10/31/2013Q313($0.10)($0.11)$1.82 million$1.50 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.11)($0.11)$1.70 million$3.00 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.11)($0.11)$2.02 million$1.60 millionViewN/AView Earnings Details
2/6/2013Q4 2012($0.10)($0.09)$1.64 million$2.32 millionViewN/AView Earnings Details
11/7/2012Q312($0.09)($0.09)$1.47 million$2.20 millionViewN/AView Earnings Details
8/1/2012($0.09)($0.09)ViewN/AView Earnings Details
11/1/2011$0.11$0.22ViewN/AView Earnings Details
8/3/2011($0.12)($0.12)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Vical (NASDAQ:VICL)
Current Year EPS Consensus Estimate: $-0.86 EPS
Next Year EPS Consensus Estimate: $-0.97 EPS


Dividend History for Vical (NASDAQ:VICL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Vical (NASDAQ:VICL)
Insider Ownership Percentage: 5.98%
Institutional Ownership Percentage: 31.47%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/11/2016Lawrence Russell SmithVPSell54$3.05$164.70View SEC Filing  
7/11/2016Lawrence Russell SmithVPSell54$4.46$240.84View SEC Filing  
6/14/2016Robert C MertonDirectorBuy9,000$4.34$39,060.00View SEC Filing  
6/9/2016Vijay B SamantCEOBuy15,700$4.72$74,104.00View SEC Filing  
6/6/2016R Gordon DouglasDirectorBuy10,078$4.41$44,443.98View SEC Filing  
6/3/2016Gary A LyonsDirectorBuy7,078$4.39$31,072.42View SEC Filing  
3/15/2016Lawrence Russell SmithVPSell8,750$0.41$3,587.50View SEC Filing  
3/3/2016Vijay B SamantCEOSell37,500$0.36$13,500.00View SEC Filing  
2/19/2016Anthony Alan RamosCAOSell7,500$0.33$2,475.00View SEC Filing  
1/25/2016Anthony Alan RamosCAOSell193$0.35$67.55View SEC Filing  
1/12/2016Vijay B. SamantCEOSell59,737$0.35$20,907.95View SEC Filing  
1/11/2016Lawrence Russell SmithVPSell974$0.36$350.64View SEC Filing  
1/11/2016Vijay B. SamantCEOSell48,535$0.35$16,987.25View SEC Filing  
1/7/2016Vijay B SamantCEOSell75,000$0.36$27,000.00View SEC Filing  
10/12/2015Lawrence Russell SmithVPSell974$0.43$418.82View SEC Filing  
10/12/2015Vijay B SamantCEOSell4,738$0.41$1,942.58View SEC Filing  
7/13/2015Igor BilinskySVPSell1,258$0.70$880.60View SEC Filing  
7/13/2015Lawrence Russell SmithVPSell974$0.70$681.80View SEC Filing  
7/13/2015Vijay B SamantCEOSell4,737$0.70$3,315.90View SEC Filing  
4/13/2015Igor BilinskySVPSell1,257$0.93$1,169.01View SEC Filing  
4/13/2015Vijay B SamantCEOSell4,738$0.93$4,406.34View SEC Filing  
3/30/2015Vijay B SamantCEOSell55,000$0.91$50,050.00View SEC Filing  
1/13/2015Vijay B SamantCEOSell4,737$1.12$5,305.44View SEC Filing  
1/12/2015Igor BilinskySVPSell1,335$1.16$1,548.60View SEC Filing  
1/12/2015Lawrence Russell SmithVPSell1,912$1.16$2,217.92View SEC Filing  
10/13/2014Igor BilinskySVPSell1,335$1.08$1,441.80View SEC Filing  
10/13/2014Lawrence Russell SmithVPSell1,912$1.08$2,064.96View SEC Filing  
10/13/2014Vijay B SamantCEOSell4,738$1.13$5,353.94View SEC Filing  
8/26/2014Anthony Alan RamosCAOSell12,500$1.25$15,625.00View SEC Filing  
7/14/2014Vijay B SamantCEOSell4,737$1.17$5,542.29View SEC Filing  
7/11/2014Lawrence Russell SmithVPSell1,912$1.16$2,217.92View SEC Filing  
4/14/2014Vijay SamantCEOSell4,738$1.16$5,496.08View SEC Filing  
4/11/2014Lawrence Russell SmithVPSell1,912$1.21$2,313.52View SEC Filing  
1/10/2014Anthony Alan RamosCAOBuy70,000$1.42$99,400.00View SEC Filing  
1/10/2014Igor BilinskyVPBuy90,000$1.42$127,800.00View SEC Filing  
1/10/2014Vijay SamantCEOBuy330,000$1.42$468,600.00View SEC Filing  
9/12/2013James R SingerMajor ShareholderSell200,000$1.29$258,000.00View SEC Filing  
9/11/2013James R SingerMajor ShareholderSell300,000$1.30$390,000.00View SEC Filing  
9/10/2013James R SingerMajor ShareholderSell200,000$1.23$246,000.00View SEC Filing  
9/9/2013James R SingerMajor ShareholderSell200,000$1.22$244,000.00View SEC Filing  
9/4/2013James Singermajor shareholderSell466,000$1.24$577,840.00View SEC Filing  
8/30/2013James Singermajor shareholderSell84,000$1.31$110,040.00View SEC Filing  
8/29/2013James Singermajor shareholderSell150,000$1.30$195,000.00View SEC Filing  
8/28/2013James Singermajor shareholderSell200,000$1.31$262,000.00View SEC Filing  
8/26/2013Anthony Alan RamosCAOBuy25,000$0.01$250.00View SEC Filing  
5/23/2013Robert C MertonDirectorBuy5,953$0.01$59.53View SEC Filing  
1/11/2013Alain P Phd RollandVPBuy22,092$0.01$220.92View SEC Filing  
1/11/2013Jill Marie BroadfootCFOBuy27,060$0.01$270.60View SEC Filing  
1/11/2013Vijay B SamantCEOBuy84,600$0.01$846.00View SEC Filing  
10/15/2012George J MorrowDirectorBuy6,394$0.01$63.94View SEC Filing  
9/24/2012James R SingerMajor ShareholderBuy154,333$3.99$615,788.67View SEC Filing  
8/31/2012James R SingerMajor ShareholderBuy310,000$3.51$1,088,100.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Vical (NASDAQ:VICL)
News IconClariVest Asset Management LLC Takes Position in Vical Inc. (VICL) - DailyQuint (NASDAQ:VICL) - October 20 at 8:14 PM logoVical Incorporated (NASDAQ:VICL) Files An 8-K (NASDAQ:VICL) - October 19 at 7:35 PM logoVical Incorporated (NASDAQ:VICL) Files An 8-K - Market Exclusive (NASDAQ:VICL) - October 18 at 7:48 PM logoVICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits (NASDAQ:VICL) - October 17 at 7:25 AM
News IconBrokerages Set $8.00 Target Price for Vical Inc. (NASDAQ:VICL) - DailyQuint (NASDAQ:VICL) - October 12 at 12:54 PM
News IconVical Starts Phase 2 Trial on Vaccine For Genital Herpes (NASDAQ:VICL) - Post News (NASDAQ:VICL) - September 26 at 7:58 PM logoVical Announces Initiation of a Phase 2 Trial of Its HSV-2 Therapeutic DNA Vaccine for Genital Herpes (NASDAQ:VICL) - September 26 at 8:45 AM logoAnalysts Dive in on Two Volatile Biotech Stocks: Sarepta Therapeutics Inc (SRPT), Vical Incorporated (VICL) (NASDAQ:VICL) - September 22 at 7:15 AM logoUnusual 11 Mid-Day Movers 9/19: (SRPT) (ISLE) (NSAT) Higher; (VICL) (MGT) (MICT) Lower - (NASDAQ:VICL) - September 20 at 6:49 AM
News IconNasdaq Index Awaiting Decisions by Federal Reserve and Bank of Japan - Economic Calendar (NASDAQ:VICL) - September 20 at 6:49 AM logoU.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.02% - (NASDAQ:VICL) - September 20 at 6:49 AM logoPre-Open Stock Movers 09/19: (ISLE) (BLOX) (TECD) Higher; (VICL) (MGT) (CYH) Lower (more...) - (NASDAQ:VICL) - September 20 at 6:49 AM logoCompany Update (NASDAQ:VICL): Vical Incorporated and Astellas Announce Topline Results from a Phase 2 Study of ... - Smarter Analyst (NASDAQ:VICL) - September 20 at 6:49 AM logoVICL Slumps, FDA Greenlights SRPT's DMD Drug, Domino Effect On PTCT - Nasdaq (NASDAQ:VICL) - September 20 at 6:49 AM logoMid-Morning Market Update: Markets Open Higher; Tech Data To Buy Technology Solutions From Avnet (NASDAQ:VICL) - September 19 at 7:51 PM logoVical and Astellas Announce Topline Results from a Phase 2 Study of (NASDAQ:VICL) - September 19 at 7:51 PM logoVical (VICL), Astellas Announce ASP0113 Phase 2 Missed Primary Endpoint in Kidney Transplant Patients (NASDAQ:VICL) - September 19 at 7:51 PM logoVical's CMV vaccine candidate flunks mid-stage study; shares off 22% premarket (NASDAQ:VICL) - September 19 at 9:55 AM logoVical (VICL), Astellas Announces ASP0113 Phase 2 Missed Primary Endpoint in Kidney Transplant Patients - (NASDAQ:VICL) - September 19 at 7:28 AM logoVICAL INC Files SEC form 8-K, Other Events (NASDAQ:VICL) - September 19 at 7:28 AM logoVical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus (CMV) Vaccine (ASP0113) in Kidney Transplant Patients (NASDAQ:VICL) - September 19 at 7:28 AM logoAstellas, Vical herpes vaccine fails mid-stage study (NASDAQ:VICL) - September 19 at 7:28 AM logo5 Stocks Under Wall Street's Radar: Acasti Pharma (NASDAQ:ACST), Vical Incorporated (NASDAQ:VICL), K2M Group ... - KC Register (NASDAQ:VICL) - September 15 at 8:04 PM logoETF’s with exposure to Vical, Inc. : September 7, 2016 (NASDAQ:VICL) - September 7 at 11:51 AM logoVical to Present at the 18th Annual Rodman & Renshaw Global Investment Conference (NASDAQ:VICL) - September 2 at 8:45 AM logoVical, Inc. :VICL-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 (NASDAQ:VICL) - August 11 at 11:35 AM logoVical Incorporated: Vical Reports Second Quarter 2016 Financial Results (NASDAQ:VICL) - August 10 at 11:22 AM logoVical's (VICL) CEO Vijay Samant on Q2 2016 Results - Earnings Call Transcript (NASDAQ:VICL) - August 10 at 11:22 AM logoVical Reports Second Quarter 2016 Financial Results - GlobeNewswire (press release) (NASDAQ:VICL) - August 9 at 11:35 AM logoVical reports 2Q loss (NASDAQ:VICL) - August 9 at 11:35 AM logoInvestor Calendar Invites You to the Vical Second Quarter 2016 Earnings Webcast Live on Tuesday, August 9, 2016 (NASDAQ:VICL) - August 8 at 8:19 PM logoVICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Fin (NASDAQ:VICL) - August 3 at 11:29 AM logoVical Incorporated: Vical Announces News Release and Conference Call Schedule for Second Quarter 2016 Financial Results (NASDAQ:VICL) - August 2 at 8:31 PM logoVical Announces News Release and Conference Call Schedule for Second Quarter 2016 Financial Results (NASDAQ:VICL) - August 2 at 7:52 AM logoVical Announces $7.8 Million Equity Investment by Partner, AnGes MG (NASDAQ:VICL) - August 1 at 6:41 AM logo6:31 am Vical confirms $7.8 mln investment from AnGes, MG (NASDAQ:VICL) - August 1 at 6:31 AM logoETF’s with exposure to Vical, Inc. : July 26, 2016 (NASDAQ:VICL) - July 26 at 12:08 PM logoLeading, Losing Stocks in Manufacturing Sector Pre Market (NASDAQ:VICL) - July 25 at 7:45 AM
News IconReasons for Lawrence Smith's Shares Sale of Vical Incorporated (NASDAQ:VICL)'s Stock - Press Telegraph (NASDAQ:VICL) - July 13 at 8:27 PM
News IconHere is What Institutional Investors Think About Vical Inc (NASDAQ:VICL) - Consumer Eagle (NASDAQ:VICL) - July 12 at 12:29 PM logoNew Study: Vical Incorporated (VICL) - Financial and Strategic SWOT Analysis Review (NASDAQ:VICL) - June 30 at 10:49 AM logoNext Weeks Broker Price Targets For Vical Incorporated (VICL) - Fiscal Standard (NASDAQ:VICL) - June 27 at 7:31 AM logoVical Incorporated (VICL) Current Analyst Ratings - Fiscal Standard (NASDAQ:VICL) - June 24 at 8:06 PM logoVical (VICL) Reports Phase I/II Data on Genital Herpes Vaccine (NASDAQ:VICL) - June 21 at 10:12 AM logoThis Weeks Broker Views For Vical Incorporated (VICL) - Fiscal Standard (NASDAQ:VICL) - June 21 at 7:22 AM logoVical’s Phase 1/2 Trial Data Presented at ASM 2016 Shows Bivalent Vaccine Imparts Reduction in Genital Herpes Lesions Durable to 9 Months (NASDAQ:VICL) - June 20 at 11:39 AM logoVical to Present HSV-2 Phase 1/2 Data at June ASM Microbe/ICAAC 2016 Conference (NASDAQ:VICL) - June 13 at 6:49 AM
News IconLyons Gary A, Director of Vical Incorporated (NASDAQ:VICL) buys 7,078 shares (NASDAQ:VICL) - June 7 at 8:24 PM logoVical (VICL) Plans Presentation of VL-2397 Data at BIO International Convention (NASDAQ:VICL) - June 2 at 11:25 AM logoVical Provides VL-2397 Updates at BIO International Convention (NASDAQ:VICL) - May 31 at 6:42 AM


Vical (NASDAQ:VICL) Chart for Monday, October, 24, 2016

Last Updated on 10/24/2016 by Staff